ACADIA Pharmaceuticals Inc. (ACAD)
| Previous close | 17.07 |
| Open | 16.98 |
| Bid | 14.59 x 100 |
| Ask | 19.43 x 100 |
| Day's range | 16.88 - 17.30 |
| 52-week range | 16.60 - 33.99 |
| Volume | |
| Avg. volume | 1,778,487 |
| Market cap | 2.795B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.37 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.40 |
Business WireAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO, April 17, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
GuruFocus.comACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.
Business WireAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
SAN DIEGO, April 02, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
